PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
131.08%
Revenue growth above 1.5x ENPH's 1.99%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
51.20%
Positive gross profit growth while ENPH is negative. John Neff would see a clear operational edge over the competitor.
No Data
No Data available this quarter, please select a different quarter.
55.54%
Operating income growth above 1.5x ENPH's 26.34%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
14.86%
Net income growth at 50-75% of ENPH's 24.63%. Martin Whitman would question fundamental disadvantages in expenses or demand.
-1378.57%
Negative EPS growth while ENPH is at 21.74%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-1378.57%
Negative diluted EPS growth while ENPH is at 22.73%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-94.15%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-94.15%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-1171.14%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-60.97%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.32%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
No Data
No Data available this quarter, please select a different quarter.